AFP
AVEO

Ausdal Financial Partners’s AVEO Pharmaceuticals, Inc. AVEO Stock Holding History

Ausdal Financial Partners’s Portfolio AVEO Stock Details AVEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-3,300
Closed -$17K – 355
2019
Q4 		$17K Hold
3,300
– – 0.01% 327
2019
Q3 		$28K Hold
3,300
– – 0.01% 306
2019
Q2 		$21K Buy
3,300
+1,000
+43% +$8.57K 0.01% 294
2019
Q1 		$19K Buy
2,300
+1,000
+77% +$10.3K 0.01% 268
2018
Q4 		$21K Sell
1,300
-200
-13% -$4.4K 0.01% 244
2018
Q3 		$50K Buy
+1,500
New +$38.6K 0.01% 413

Other funds holding AVEO

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
XSC
X-Square Capital Guaynabo, Puerto Rico $297M AUM 32.87% 1-Year Est. Return
WG
Winton Group London, United Kingdom $2.85B AUM 30.73% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Ausdal Financial Partners's AVEO Position: Q1 2020 in Review

Ausdal Financial Partners sold out of AVEO Pharmaceuticals, Inc. (AVEO) in Q1 2020, closing a stake of 3,300 shares — an estimated $17K sold.

Ausdal Financial Partners first reported a position in AVEO in Q3 2018 and held it in 6 quarters. The position peaked at $50K in Q3 2018. 35 funds tracked by Wall St. Rank hold AVEO as of Q1 2020.

  • Ausdal Financial Partners reported no remaining AVEO Pharmaceuticals, Inc. position as of Q1 2020 after selling out during the quarter.
  • Ausdal Financial Partners sold 3,300 AVEO Pharmaceuticals, Inc. shares in Q1 2020, an estimated $17K.
  • Ausdal Financial Partners first reported a position in AVEO Pharmaceuticals, Inc. in Q3 2018 and held it in 6 quarters.
  • Ausdal Financial Partners's AVEO Pharmaceuticals, Inc. position peaked at $50K in Q3 2018.
  • 35 funds tracked by Wall St. Rank held AVEO Pharmaceuticals, Inc. as of Q1 2020.

Based on Ausdal Financial Partners's 13F filing for Q1 2020, filed 4 May 2020.